• Background
• Scope and Methodology
• Size and Growth of Market
• Market Trends

Overview of Neurologic Diseases and Disorders

• Multiple Sclerosis

Treatment of Neurologic Diseases and Disorders

Demyelinating Diseases

• Relapsing-Remitting Multiple Sclerosis
• Secondary-Progressive Multiple Sclerosis
• Other Forms of Multiples Sclerosis
• Other Demyelinating Diseases

Progress and Promise in Therapeutics Development

Genetics and Neurogenomics

Neural Implant Technologies

Miscellaneous Advances


• Vascular Endothelial Growth Factor (VEGF)
• Minocycline
• Stroke and Apoptosis

Clinical Trial Activity

World Market Analysis

Background

The Markets by Geography


• The United States
• France
• Germany
• Italy
• Spain
• United Kingdom
• Japan

The Market by Applications


• Multiple Sclerosis

Company Profiles

• Cortex Pharmaceuticals, Inc.
• Elan Corporation plc
• Guilford Pharmaceuticals Inc.
• Neurocrine BioSciences, Inc.
• Pharmos Corporation

Conclusions and Strategic Implications

• First Conclusion
• Second Conclusion
• Third Conclusion
• Fourth Conclusion
• Fifth Conclusion
• Sixth Conclusion
• Seventh Conclusion

Glossary

Company Directory

List of Exhibits

• Table 1-1: Estimated Market Sizes for the Top Five Applications Segments for Neurotherapeutics in the Major World Healthcare Markets, 2001-2009
• Table 1-2: Estimated Market Sizes for the Geographic Segments for Neurotherapeutics in the Major World Healthcare Markets, 2001-2009
• Table 3-1: Comparison of Modern Drugs for the Treatment of Relapsing- Remitting Multiple Sclerosis
• Table 4-1: Known Genetic Alternation in Neurologic Neoplasms
• Table 5-1: The Potential for Neurotherapeutics in the Seven Major World Healthcare Markets, 2001-2010
• Table 5-2: The Potential for Neurotherapeutics in the United States by Application, 2001-2010
• Table 5-3: The Potential for Neurotherapeutics in France by Application, 2001-2010
• Table 5-4: The Potential for Neurotherapeutics in Germany by Application, 2001-2010
• Table 5-5: The Potential for Neurotherapeutics in Italy by Application, 2001-2010
• Table 5-6: The Potential for Neurotherapeutics in Spain by Application, 2001-2010
• Table 5-7: The Potential for Neurotherapeutics in the United Kingdom by Application, 2001-2010
• Table 5-8: The Potential for Neurotherapeutics in Japan by Application, 2001-2010 82
• Table 5-9: The Potential for Neurotherapeutics in the Major World Healthcare Markets by Application 2001-2010
• Table 5-16: The Potential for Multiple Sclerosis Therapeutics in the Major World Healthcare Markets 2001-2010
• Figure 1-1: Incidence of Major Neurologic Diseases in the Major World Healthcare Markets, 2001-2010
• Figure 1-2: The Total Market for Neurotherapeutics in the Major World Healthcare Markets, 2001-2010
• Figure 1-3: Growth Rates in the World’s Seven Major Neurotherapeutics Markets by Application, 2001-2009
• Figure 1-4: Growth Rates in the World’s Seven Major Neurotherapeutics Markets by Geographic Region, 2001-2009
• Figure 1-5: Composition of the Markets for Neurotherapeutics by Applications Segment, 2002 and 2010
• Figure 1-6: Composition of the Markets for Neurotherapeutics by Geographic Segment, 2002 and 2010
• Figure 2-1: Structure of the Normal Motor Neuron
• Figure 4-1: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 1-4
• Figure 4-2: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 5-8
• Figure 4-3: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 9-12:
• Figure 4-4: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 13-16
• Figure 4-5: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 17-20
• Figure 4-6: Genes Associated with Neurologic Diseases and Disorders: Chromosomes 21, 22, X, and Y
• Figure 5-1: Growth Rates in Neurotherapeutics Potential for the Seven Major World Healthcare Markets, 2001-2010
• Figure 5-2: Distribution of the Estimated Market Potential for Neurotherapeutics in the Seven Major World Healthcare Markets, 2002
• Figure 5-3: Growth Rates in Neurotherapeutics Market Opportunities 2001-2010
• Figure 5-4: Distribution of the Estimated Market Potential for Neurotherapeutics in the Seven Major World Healthcare Markets by Application, 2002